Market Downturn: Biotech and Tech Stocks Face Sharp Declines Amidst High Selling Volume

Font: Financial Modeling Prep  • May 14, 2026

• Biotechnology stocks and technology stocks experienced significant declines driven by high selling volume and company-specific news.
• Key factors like clinical trial data and quarterly earnings reports heavily influenced investor sentiment, leading to sharp stock price drops.
• High trading volumes confirmed strong selling pressure, indicating investors are closely scrutinizing financial results and strategic decisions in the current market environment.

The stock market saw several key stocks face significant downturns. Companies in biotechnology and technology sectors experienced sharp declines driven by high selling volume. This was evident in the performance of REGENXBIO Inc. (NASDAQ: RGNX), Doximity, Inc. (NYSE: DOCS), Robinhood Ventures Fund I (NASDAQ: RVI), NYSE:MEI, and NIQ Global Intelligence Plc (NYSE: NIQ), as investors reacted to new company-specific information.

REGENXBIO Inc. (NASDAQ: RGNX) saw its stock price fall by 37.80% to $6.25. The drop followed the release of trial data for its gene therapy candidate, RGX-202. Trading volume surged to nearly 10 million shares, showing a strong negative investor reaction to the update as the stock neared its day low of $6.02.

Doximity, Inc. (NYSE: DOCS) shares fell 23.00% to $18.01 after its fourth-quarter earnings report. While revenues were higher than expected, Doximity missed its earnings targets and had declining profit margins. Profit margins show how much profit a company makes from its sales, so a decline can worry investors about future profitability.

Other technology-related firms also saw declines. Robinhood Ventures Fund I (NASDAQ: RVI) dropped 22.30% to $57.27 after announcing a $75 million investment in OpenAI. NIQ Global Intelligence Plc (NYSE: NIQ) fell 18.33% to $8.20, even after reporting strong first-quarter financial results that exceeded expectations, with revenue growing 11.1%.

Today's market losers show that stock prices react to more than just headlines. High trading volumes confirmed strong selling pressure across the board. Investors closely analyzed earnings reports, clinical trial data, and strategic investments, leading to significant stock price drops even when some news appeared positive on the surface.